Replies to post #4400 on Biotech Values

[swampboots]

"At R&R, Levitt seemed almost resigned to the fact that no single therapy is likely to triumph over AMD and that stabilization of vision is a more realistic goal."

For first time have let go of some original shares because absence of improvement expectations has smothered die hard hold on all shares.

[randychub]

Safety Issues - I don't believe there are any. He mentioned how safe the drug was many times.

"I sensed Levitt’s backing off to some degree from prior assertions that it’s reasonable for investors to expect Squalamine to blow away the competition by improving vision for a substantial proportion of patients by 3+ lines relative to baseline (the standard definition of improved vision). At R&R, Levitt seemed almost resigned to the fact that no single therapy is likely to triumph over AMD and that stabilization of vision is a more realistic goal."

I think this is a good move. Squal can be a very successful drug with results similiar to the competition. Also if you show the drug as on going therapy the market is larger.

10mg may be used sub-Q or topical (17:47), patients may be able to treat themselves, or more frequent appts with less drug being used. This is good news to me. I see nothing negative in the 10mg dosage. Good move to study the 10mg dosage.

I also have no problem with partnership talks being delayed. Things at this point are moving along well. It would be nice if a partnership is done after we see some good phase II results and before phase 3 starts.

Randy